DiaMedica Inc. Announces Public Offering
December 04 2013 - 12:12PM
Marketwired
DiaMedica Inc. Announces Public Offering
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec 4, 2013) - DiaMedica
Inc. (TSX-VENTURE:DMA), announced today that it has filed a
preliminary short form prospectus in connection with the public
offering (the "Offering") of units of DiaMedica (the "Units"). The
Offering is being placed on a commercially reasonable efforts
agency basis by Jordan Capital Markets Inc. (the "Agent").
Each Unit is currently
expected to consist of one common share in the capital stock of
DiaMedica and one-half of one common share purchase warrant, with
each whole warrant entitling the holder thereof to purchase one
common share within two years from the initial closing date of the
offering, subject to an acceleration of the expiry date of such
warrants in certain circumstances as more particularly described in
the prospectus.
The Offering size, price of
the Units and the exercise price of the warrants will be determined
by DiaMedica and the Agent in the context of the market.
DiaMedica intends to use the
net proceeds from the Offering for research and development
including a Phase II clinical trial for Type 2 diabetes, and for
working capital and general and administrative purposes as
described in the prospectus.
About DiaMedica
DiaMedica is a
biopharmaceutical company that develops novel therapeutic products
designed to improve the lives of people with Type 1 diabetes, Type
2 diabetes and other large, medically unmet diseases. DiaMedica's
lead product candidate, DM-199, has been shown to protect and
proliferate beta cells and significantly improve glucose metabolism
in preclinical models.
The Company is listed on the
TSX Venture Exchange under the trading symbol 'DMA'.
FORWARD-LOOKING STATEMENTS
The statements made in this
press release that are not historical facts contain forward-looking
information that involves risk and uncertainties. All statements,
other than statements of historical facts, which address
DiaMedica's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of
business judgment as well as assumptions made by and information
currently available to management. When used in this document, the
words "may", "will", "anticipate", "believe", "estimate", "expect",
"intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on
these forward-looking statements. These statements reflect a
current view of future events and are subject to certain risks and
uncertainties as contained in the Company's filings with Canadian
securities regulatory authorities. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially
from those anticipated in these forward-looking statements. The
Company undertakes no obligation, and does not intend, to update,
revise or otherwise publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof, or to reflect the occurrence of any unanticipated
events. Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
Neither the TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this
News Release.
DiaMedicaRick PaulsPresident and
CEO763-710-4455info@diamedica.comDiaMedicaOne Carlson Parkway,
Suite 124Minneapolis, MN
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024